HOME PAGE

CORPORATE PROFILE

THE MBE TEAM

OUR SEARCH PROCESS

CURRENT SEARCHES

COMPLETED SEARCHES

FAVORITE LINKS

RECENT QUOTES & EVENTS

PRESS RELEASES

CONTACT US



Press Releases

Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer

MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of Sanjay S. Subramanian, MBA, to the role of Chief Financial Officer, effective October 1, 2019. More.


BlueSphere Bio Names Veteran Biotech Leader David Apelian as CEO - with Pitt Expertise and UPMC Funding, BlueSphere's TCXpress Platform to Develop Rapid, Personalized T-Cell Therapies for Cancer Treatment - 7/31/2019

PITTSBURGH -- BlueSphere Bio, an immunotherapy startup formed by UPMC Enterprises and focused on creating personalized therapies for cancer, announced today that David Apelian, M.D., Ph.D., M.B.A., has been named chief executive officer of the company. He joins top clinical immunology experts and company co-founders Mark Shlomchik, M.D., Ph.D., and Warren Shlomchik, M.D., of the University of Pittsburgh to advance the TCXpress platform to develop rapid, personalized T-cell therapies for cancer. More.


Agilvax, Inc. Appoints Joseph Patti, Ph.D. as Executive Chairman

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Agilvax, Inc. a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman. More.


Advaxis, Inc. announces the Appointment of Andres A. Gutierrez as Executive Vice President, Chief Medical Officer

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced Andres A. Gutierrez, M.D., Ph.D. has been named Executive Vice President, Chief Medical Officer, effective April 23, 2018. More.


SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer

NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Gene Mack as Chief Financial Officer and Treasurer. More.


Pacira Pharmaceuticals, Inc. announces the Appointments of Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing – Emerging Therapies

PARSIPPANY, N.J., Oct. 20, 2016 - Pacira Pharmaceuticals, Inc. (PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Sluby has been named Vice President, Sales and Matthew Lehmann has been appointed Vice President, Marketing – Emerging Therapies; both individuals will report to Robert Weiland, Chief Commercial Officer. More.


Noxilizer announces David A. Theil, Senior Vice President And CFO

Experienced Life Science Financial Executive Joins Management Team
January 26, 2016 (Baltimore, MD) Noxilizer, Inc., the company advancing a room temperature, NO2-based sterilization and decontamination process for bio-pharmaceutical and medical device manufacturers announces David A. Theil as their new Senior Vice President and Chief Financial Officer (CFO). More.


BD announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development

Franklin Lakes, NJ (March 13, 2013) – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company’s Management Committee and Leadership Team. In her new role, Dr. Strahlman will oversee the Company’s Medical Affairs and Research & Development functions. More.



MBELS STAFF:
CONTACT MBELS

Site Designed & Maintained by Susan Ivankovich Web Design